Orion Pharma (DHA:ORIONPHARM) PEG Ratio: N/A (As of Jul. 01, 2026)


DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
69 GF Score
Price BDT28.60
GF Value BDT20.31
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Orion Pharma's PE Ratio without NRI is 0.00. Orion Pharma's 5-Year EBITDA growth rate is -20.30%. Therefore, Orion Pharma's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Orion Pharma's PEG Ratio or its related term are showing as below:


During the past 12 years, Orion Pharma's highest PEG Ratio was 19.88. The lowest was 0.80. And the median was 3.06.


DHA:ORIONPHARM's PEG Ratio is not ranked *
in the Utilities - Independent Power Producers industry.
Industry Median: 2.01
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Orion Pharma  (DHA:ORIONPHARM) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Orion Pharma PEG Ratio Related Terms


Orion Pharma PEG Ratio Historical Data

* Premium members only.

The historical data trend for Orion Pharma's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma PEG Ratio Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.80 3.00 9.34 0.00 0.00

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DHA:ORIONPHARM vs CEG, VST, NRG: PEG Ratio Comparison

For the Utilities - Independent Power Producers subindustry, Orion Pharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Pharma PEG Ratio vs Utilities - Independent Power Producers Industry

For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Orion Pharma's PEG Ratio falls into.


DHA:ORIONPHARM
69GF Score
Orion Pharma Ltd DHA:ORIONPHARM
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Orion Pharma's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-20.30
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT28.60 is trading 40.8% above its estimated GF Value™ of BDT20.31. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • PEG Ratio: N/A
  • GF Value™: BDT20.31 vs. price of BDT28.60 (40.8% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score

Get the complete analysis for DHA:ORIONPHARM

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT28.60
Price
BDT20.31
GF Value